Xenin-25[Lys(13)PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential

Victor Gault, CM Martin, Peter Flatt, Parthsarathy V, Nigel Irwin

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

AIMS: Xenin-25 is co-secreted with glucose-dependent insulinotropic polypeptide (GIP) from intestinal K-cells following a meal. Xenin-25 is believed to play a key role in glucose homoeostasis and potentiate the insulinotropic effect of GIP.METHODS: This study investigated the effects of sub-chronic administration of the stable and longer-acting xenin-25 analogue, xenin-25[Lys(13)PAL] (25 nmol/kg), in diabetic mice fed with a high-fat diet.RESULTS: Initial studies confirmed the significant persistent glucose-lowering (p <0.05) and insulin-releasing (p <0.05) actions of xenin-25[Lys(13)PAL] compared with native xenin-25. Interestingly, xenin-25 retained significant glucose-lowering activity in GIP receptor knockout mice. Twice-daily intraperitoneal (i.p.) injection of xenin-25[Lys(13)PAL] for 14 days had no significant effect on food intake or body weight in high-fat-fed mice. Non-fasting glucose and insulin levels were also unchanged, but overall glucose levels during an i.p. glucose tolerance and oral nutrient challenge were significantly (p <0.05) lowered by xenin-25[Lys(13)PAL] treatment. These changes were accompanied by significant improvements in i.p. (p <0.05) and oral (p <0.001) nutrient-stimulated insulin concentrations. No appreciable changes in insulin sensitivity were observed between xenin-25[Lys(13)PAL] and saline-treated high-fat mice. However, xenin-25[Lys(13)PAL] treatment restored notable sensitivity to the biological actions of exogenous GIP injection. Consumption of O2, production of CO2, respiratory exchange ratio and energy expenditure were not altered by 14-day twice-daily treatment with xenin-25[Lys(13)PAL]. In contrast, ambulatory activity was significantly (p <0.05 to p <0.001) increased during the dark phase in xenin-25[Lys(13)PAL] mice compared with high-fat controls.
Original languageEnglish
Pages (from-to)461-471
JournalActa Diabetologica
Volume52
Issue number3
DOIs
Publication statusPublished - 1 Jun 2015

Keywords

  • Xenin
  • GIP
  • Diabetes
  • Obesity
  • Glucose tolerance

Fingerprint Dive into the research topics of 'Xenin-25[Lys(13)PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential'. Together they form a unique fingerprint.

Cite this